• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169449 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
+ i  ]' O/ J3 e; w* Y4 g7 |
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  1 h2 s7 @2 L( i& ]+ I" o6 g
% B" k! q) \, r

" P: _0 F: w/ f$ i, v# w: {) V, V, kSub-category:% j, l6 D, f6 ~, Z+ R
Molecular Targets % j6 V* z9 u- r; Y6 x! I

$ r8 ?" v0 U0 r3 c* |! M9 r, z: [+ C
Category:4 V7 D6 O1 ?8 x: o) d
Tumor Biology " M& g% p& I( N8 l

0 g+ u- e3 |; a' d2 r9 M& Y" A7 h% N) p9 |' n+ J* W0 N
Meeting:
: |* o% U+ |5 _. w2011 ASCO Annual Meeting & Y' Z& Q# C$ \, @

, ]+ _6 g+ E1 r9 W& K/ A3 ^; m5 g/ _& \( J
Session Type and Session Title:
' y/ K+ o; |4 }2 `Poster Discussion Session, Tumor Biology
. A6 i# d/ R3 I+ c0 V
0 S3 T( B, d! {4 G: H
) z; P( E( X2 g) R4 q0 ]7 pAbstract No:, n) H* u) Y) N. k4 G/ x; w3 e0 F
10517
" \+ H! C1 Y/ |
7 O% B0 T/ E8 N* ^$ ?; J' F; Z- t9 Z# Q
Citation:+ v& t" o" N$ Y' ^9 q
J Clin Oncol 29: 2011 (suppl; abstr 10517)
# p) [) ?7 ?- E+ ~  u
6 r7 R3 L4 Z9 f
* e( q8 m9 A& m& ZAuthor(s):2 [# @: `) P/ n$ n4 j- r+ X' h
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 9 o5 {, \- P& r! v- [4 c8 ^
2 h$ ~: X6 Q, k6 t- _0 h) _

2 U) ~7 e" h+ H6 L# ^& ~
' |- n/ m! k) |( ~  |6 ^6 f3 q1 SAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.7 s# \- `0 w0 _
7 X$ z6 \  i- ^. x1 G
Abstract Disclosures
/ m) _) z3 a4 R/ p- ^/ s- [6 Q9 L# x( s: K. ]: }
Abstract:
1 Y* W! o& \5 J' j( Y# \* ^
4 ]7 p5 K- c9 Z7 U+ `0 ?" Z+ I
* H/ W, a6 i* k* E- ?Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.; D- ]9 b: d7 m" j8 Y1 x

/ l, i7 u  Z0 C   p) g; P: P; [+ W9 r
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37
3 P5 w4 Y/ x* i5 o5 G8 k没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
3 Y" I: n9 A6 o1 V) h0 u2 O0 S
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
5 a* ^: S1 D7 R$ t  a6 U2 [易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
, g. c! ]! m( G; Y# WALK一个指标医院要900多 ...

+ U: b6 n2 H! S6 Z平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?1 Y+ W2 D# ~; g6 K- R/ v9 k6 Q0 Z
  B; s% k. J& s
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表